The potent and highly selective RET* inhibitor BLU-667 was well-tolerated and exhibited promising clinical activity among patients with advanced, RET-altered solid cancers that progressed despite multikinase inhibitor therapy, according to data presented at AACR 2018.
A dual-inhibition immunotherapeutic regimen consisting of the highly selective IDO1* inhibitor epacadostat and the PD-L1** inhibitor durvalumab was safe for advanced solid tumours, according to findings from the ongoing ECHO-203*** study presented at AACR 2018.
The addition of pembrolizumab to a pemetrexed-platinum chemotherapy regimen improved overall survival (OS) and progression-free survival (PFS) in patients with advanced non-squamous non-small-cell lung cancer (NSCLC), findings from the phase III KEYNOTE-189* trial show.
Pembrolizumab delivered intravenously every 3 weeks for 1 year extended recurrence-free survival (RFS) in patients with resected stage III melanoma, according to results of the KEYNOTE-054/EORTC 1325-MG* trial.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).